✓
Open
21 Jun 2024
✓
Close
25 Jun 2024
3
Allotment
—
✓
Listing
Fri, Jun 28, 2024
Price Band
₹32 to ₹34
Issue Size
31,00,000 shares (agg. up to ₹11 Cr)
Lot Size
4,000 Shares
Listing Date
Fri, Jun 28, 2024
Latest GMP
₹70
Est. Gain
205.88%
✦ AI Insight
GMP Trend
28-06-2024₹70Est. ₹104+205.88%
27-06-2024₹70Est. ₹104+205.88%
26-06-2024₹50Est. ₹84+147.06%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 688.51x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 38.58 | 32.12 | 27.07 | 26.34 |
| Total Income | 25.29 | 22.96 | 21.19 | 25.06 |
| Profit After Tax | 2.40 | 0.96 | 0.09 | 0.30 |
| NET Worth | 15.18 | 8.52 | 7.56 | 7.47 |
| Reserves and Surplus | 6.58 | 2.52 | 1.56 | 1.47 |
| Total Borrowing | 12.66 | 11.80 | 10.25 | 9.59 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Quest Laboratories Ltd. | SME | ₹43.16 Cr | ₹97 | 23.03 | ₹147.35 | +51.91% | ₹96.95 (+8.08%) |
| Zenith Drugs Ltd. | SME | ₹40.68 Cr | ₹79 | 18.4 | ₹105.15 | +33.10% | ₹50.10 (-4.48%) |
| Sunrest Lifescience Ltd. | SME | ₹10.85 Cr | ₹84 | 12.33 | ₹79.80 | -5.00% | ₹35.00 (-1.69%) |
| Mono Pharmacare Ltd. | SME | ₹14.84 Cr | ₹28 | null | ₹30.45 | +8.75% | ₹10.75 (+4.88%) |
| Shelter Pharma Ltd. | SME | ₹16.03 Cr | ₹42 | 5.62 | ₹41.96 | -0.10% | ₹26.00 (+1.96%) |
| Innova Captab Ltd. | Mainboard | ₹570.00 Cr | ₹448 | 31.64 | ₹541.40 | +20.85% | ₹1,011.30 (+2.04%) |
| Blue Jet Healthcare Ltd. | Mainboard | ₹840.27 Cr | ₹346 | 37.49 | ₹413.40 | +19.48% | ₹588.15 (-1.65%) |
| Valiant Laboratories Ltd. | Mainboard | ₹152.46 Cr | ₹140 | 15.71 | ₹170.25 | +21.61% | ₹63.60 (-1.68%) |
| Concord Biotech Ltd. | Mainboard | ₹1,550.52 Cr | ₹741 | 32.29 | ₹942.80 | +27.23% | ₹1,346.00 (+0.23%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding of expenses proposed to be incurred towards Product registration in the international markets | 3.00 |
| 2 | Plant updation and increase in production capacity | 2.25 |
| 3 | Funding working capital requirements of our Company | 4.00 |
| 4 | General corporate purpose | 0.39 |
About Medicamen Organics IPO
Medicamen Organics Limited was incorporated in 1995 and develops, manufactures, and distributes pharmaceutical dosages including generic dosages in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions and dry powders for the Government (including State Governments and Central Governments) and private entities as a contract manufacturer/third party manufacturer. The company's product list comprises 84 products and offers a wide range of drugs such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral and non-steroidal anti-inflammatory drugs (NSAIDS). The company's products are marketed throughout India as well as in African, CIS, and South East Asian countries such as Congo, Benin, Kameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya through third-party distributors. The company has two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, covering an area of 21,536 Sq. Ft. As on September 30, 2023, the company has entered into con
Contact Details
Medicamen Organics Ltd. Address10 Community CentreNo 2 Ashok Vihar Phase IINew Delhi, New Delhi, 110052+91-9818222845cs@mediorganics.inVisit Website